ArticleCureus2026
Hepatic Epithelioid Angiomyolipoma: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatic epithelioid angiomyolipoma (HEAML) is a rare mesenchymal tumor belonging to the family of perivascular epithelioid cell tumors (PEComas), a group of mesenchymal neoplasms characterized by the proliferation of distinctive perivascular epithelioid cells expressing both melanocytic and smooth muscle markers. Because of its hypervascular nature and nonspecific imaging features, HEAML can closely mimic other hypervascular hepatic lesions, including hepatocellular carcinoma, hepatic adenoma, and focal nodular hyperplasia, making accurate preoperative diagnosis challenging. A 42-year-old woman was incidentally found to have a hepatic mass in the left lobe during a routine health examination. Abdominal ultrasonography revealed a relatively homogeneous hypoechoic lesion with well-defined margins and mild bulging of the liver capsule, containing thin internal echogenic strands. Magnetic resonance imaging demonstrated a mild signal drop on out-of-phase images compared with in-phase images, suggesting the presence of microscopic fat. Following contrast administration, the lesion showed strong heterogeneous arterial enhancement with punctate and linear intratumoral vessels, followed by prolonged enhancement in the portal venous and delayed phases ("wash-in, slow-out"). Early enhancement of a draining vein connected to the left portal vein branch was also observed. The patient underwent surgical resection. Histopathological examination revealed epithelioid cells with clear cytoplasm arranged around thin-walled blood vessels, without necrosis or significant mitotic activity. Immunohistochemical analysis showed positivity for HMB45, Melan-A, and smooth muscle actin, and negativity for HepPar-1, cytokeratin, and CD117, confirming the diagnosis of HEAML. HEAML is a rare hepatic tumor in which the integration of imaging findings and immunohistochemical analysis is essential for achieving an accurate diagnosis and guiding appropriate clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.